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Abstract
Background: Early suppression of disease activity in (rheumatoid) arthritis (RA) patients may result in drug-free
remission and prevent damage. We assessed 2-year clinical and radiological outcomes of two disease activity score
(DAS)-remission-steered treatment strategies in early arthritis patients.
Methods: Patients (n = 610) with early RA or undifferentiated arthritis (UA) were treated with methotrexate (MTX)
and tapered high dose of prednisone. Patients in early remission (44/53 joints DAS <1.6) after 4 months tapered
and stopped medication. Patients who did not achieve early DAS-remission were randomized to either MTX plus
hydroxychloroquine plus sulphasalazine plus low dose prednisone (arm 1) or to MTX + adalimumab (arm 2). At four-
monthly intervals, medication was tapered and stopped if DAS was <1.6 but restarted, increased or switched if DAS
was ≥1.6. Proportions of (drug-free) DAS-remission (DFR) after 2 years and Sharp-van der Heijde scores (SHS) were
analyzed separately for the treatment strategies and patients with RA and UA.
Results: After 2 years, 301/610 (49 %) patients were in DAS-remission and 131/610 (21 %) in DFR. In the early
remission group 241/387 patients (62 %) were in DAS-remission and 111/387 (29 %) DFR. In arm 1 22/83 (27 %) and
in arm 2 24/78 (31 %) were in DAS-remission, and 6/83 (7 %) and 7/78 (9 %), respectively, were in DFR. RA and UA
patients achieved DAS-remission in comparable percentages (RA: 234/479 (49 %), UA: 64/122 (52 %), p = 0.25). More
UA patients achieved DFR (41/122 (34 %)) compared to RA patients (89/479 (19 %), p<0.001). Mean (SD) DAS over
time was 1.74 (0.58) across all patients, and median (IQR) SHS progression was 0 (0–0).
Conclusions: After 2 years remission-steered treatment in early RA and UA patients, DAS-remission and DFR
percentages were relatively low. Patients who achieved early remission more often achieved (drug-free) remission
after 2 years than patients who needed additional treatment steps in the randomization arms, and more UA than
RA patients achieved DFR. Overall, disease activity and radiologic damage progression in all patients were well
suppressed.
Trial registration: http://www.controlled-trials.com/ISRCTN11916566 Registered 07/11/2006 and EudraCT number 2006-
06186-16 Registered 16/07/2007.
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Background
In recent decades the treatment of rheumatoid arthritis
(RA) has considerably changed, aiming at earlier suppres-
sion of disease activity, resulting in better outcomes [1–3].
The need to start disease-modifying antirheumatic drugs
(DMARDs) earlier is incorporated through new classifica-
tion criteria for RA [4], which include patients in earlier
phases of the disease process. In addition, several trials
have included or focused on patients with arthritis not
(yet) fulfilling these criteria (undifferentiated arthritis
(UA)) [5–13]. It has become clear that treatment to target
prevents gradual deterioration [14, 15]. Based on results
of clinical trials with treatment to target, in which a large
percentage of RA patients achieved clinical remission
[16–18], it is suggested that remission should be the treat-
ment target [15]. Several trials [5, 16–20] have shown that
initial treatment with a combination including methotrex-
ate (MTX) and corticosteroids results in earlier suppres-
sion of inflammation and damage progression. It is
hypothesized that induction of early remission may pre-
vent chronicity of arthritis and allow tapering of treatment
to drug-free remission (DFR) [21]. In UA this may be even
more readily achieved, although in the PROMPT study,
monotherapy with MTX proved insufficient to perman-
ently induce remission in patients with UA [10].
The IMPROVED study was designed following the
intention and results of these studies. It aims to achieve
early clinical remission, followed by tapering of medica-
tion to DFR. Patients both with early RA (based on the
new classification criteria) and with UA were included,
and treated according to the same protocol, starting with
a combination of MTX with prednisone, then tapering
or adding DMARDs, depending on whether treatment-
target clinical remission has been achieved. In this
secondary analysis of the IMPROVED-study, the clinical
and radiological outcomes of 2 years of remission-
targeted treatment are presented.
Methods
Study design
The IMPROVED study (ISRCTN11916566 and EudraCT
number 2006-06186-16) is a multicentre two-step ran-
domized single-blinded clinical trial designed by Dutch
rheumatologists participating in the Foundation for
Applied Rheumatology Research (FARR). Patients were
recruited between March 2007 and September 2010 in 12
hospitals in the Western part of the Netherlands. The
study protocol was approved by the Medical Ethics
Committee of each participating centre (listed in
“Acknowledgements”).
Patients
Patients were ≥18 years old, with early RA or UA, a
disease activity score (DAS) ≥1.6, and no previous
antirheumatic therapy. RA was defined as fulfilling the
2010 American College of Rheumatology (ACR) and
European League Against Rheumatism (EULAR) classifi-
cation criteria [4] with a symptom duration ≤2 years. UA
was defined as at least one joint with clinical synovitis
and one other painful joint, clinically suspected as due
to early RA, regardless of symptom duration. Exclusion
criteria were previously published [13, 22]. All patients
gave written informed consent.
Intervention
All patients started with 4 months of MTX 25 mg/week
and prednisone 60 mg/day tapered to 7.5 mg/day in
7 weeks. Every 4 months the DAS (based on a 44-
swollen-joint count and the Richie articular index, both
including the feet) [23] was assessed by a trained research
nurse, blinded for treatment allocation. The treatment
target of the study was a DAS <1.6, which was considered
to denote remission (Fig. 1) [24].
Patients in early remission (DAS <1.6 after 4 months)
tapered prednisone with in 3 weeks with a dose reduc-
tion of 2.5 mg/day each week to 0 mg/day. When still in
remission after 8 months, MTX was also tapered to 0
within 10 weeks (every week tapered with 2.5 mg/wk).
In patients with a DAS ≥1.6 after 8 months, prednisone
was restarted at 7.5 mg/day.
Patients with a DAS ≥1.6 after 4 months were ran-
domized, either to hydroxychloroquine (HCQ) 400 mg/
day and sulphasalazine (SSZ) 2000 mg/day added to
MTX and prednisone (arm 1), or they switched to MTX
25 mg/week plus adalimumab (ADA) 40 mg/2 weeks
(arm 2). Patients who had achieved early remission and
discontinued prednisone, then lost remission and
restarted prednisone without achieving remission, were
also randomized to arm 1 or 2 (delayed randomization)
(Fig. 1). In arm 1, if remission after 8 months was
achieved, prednisone, SSZ and then HCQ were stopped.
MTX was stopped if remission remained 4 months later.
If remission was not achieved at 8 months, patients
switched to MTX +ADA (40 mg/2 weeks, increased to
40 mg/week if DAS remained ≥1.6). Patients in arm 2
tapered ADA in they were in remission after
8 months, and increased ADA to 40 mg/week if there
was no remission. The weekly dose of ADA (in com-
bination with MTX) was exploratory and is not evi-
dence based. Based on the costs of medication, and
in view of a subsequent report on dose-dependent
risk of side effects, ADA 40 mg/week is not approved
in current daily practice [25].
In both arms, if patients did not achieve remission on
a combination of MTX +ADA 40 mg/week, further
treatment decisions were left to the opinion of the
rheumatologist (Fig. 1). A detailed description of the
randomization procedure was previously published [22].
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Primary and secondary outcomes
Primary outcomes were percentages of patients in DAS-
remission and DFR based on a DAS <1.6. Secondary
outcomes were DFR based on the proposed remission
definition published by the ACR/EULAR in 2011
(Boolean) [26] mean DAS, mean functional ability as
measured by the Dutch version of the health assess-
ment questionnaire (HAQ) [27], radiological evidence
of damage progression in the joints of the hands and
feet (defined as an increase ≥0.5 points in the Sharp-van
der Heijde score (SHS)) [28] and toxicity.
Baseline and yearly radiographs of the hands and feet
were anonymized and scored in time-random order for
the presence of erosions and joint space narrowing, by
two trained, independent readers (LH and GA). Only
8 % of the patients had progression and therefore intra-
class correlation coefficients were not suitable for meas-
uring reliability [29]. In 443 of 496 patients who had ra-
diographs taken after 2 years follow up, there was an
inter-reader difference <2 between the progression
scores of both readers. Consensus on score was reached
for the other 53 patients.
Outcomes were reported separately for patients who
achieved early DAS-remission and those randomized
and were compared between the randomization arms,
and between RA and UA patients, and between patients
who were in remission or not in remission after 2 years.
Treatment during 2 years was plotted in a figure
as percentages of patients on medication per treat-
ment group. The figure shows not treatment steps,
but actual medication use, with medications catego-
rized as ‘other’ being those that were prescribed
either according to the protocol after failure on ADA
(treatment according to physician) or outside the regular
treatment steps, although still DAS-remission-steered
(outside of protocol).
Statistical analysis
We performed intention-to-treat analyses. Outcomes were
compared using Student’s t test, the Mann–Whitney U
test and the chi square (χ2) test. DAS and HAQ over time
were compared using linear mixed models (LMM), with
treatment strategy (arms 1 and 2) and time (study visit) as
fixed effects in an unstructured covariance structure.
All statistical analyses were conducted with SPSS for
Windows version 20.0.
Results
Study population
Of the 610 patients, 479 (79 %) had classifiable RA
(2010 criteria) and 122 (20 %) UA (9 patients could not
be classified because of missing data). Of 610 patients,
387 (63 %) achieved early DAS-remission at 4 months
(early remission group). Of the 610 patients, 161 (26 %)
with DAS ≥1.6 at 4 months were randomized, 83
patients to arm 1 and 78 to arm 2. Fifty patients with a
DAS ≥1.6 at 4 months were not randomized because the
treating physician declared the patient in clinical remis-
sion. These patients were analyzed in the outside-of-
protocol (OOP) group. Twelve patients left the study be-
fore the assessment at 4 months (Table 1). Over 2 years
79 patients were lost to follow up; 54 withdrew consent,
9 discontinued because of a revised diagnosis and 8 be-
cause of co-morbidity. Eight patients died [13, 22], of
Fig. 1 Study flow chart with percentages disease activity score (DAS) and drug-free remission after the second study year. Orange prednisone,
green methotrexate (MTX), dark blue treatment according to opinion of rheumatologist (TAR), aqua hydroxychloroquine (HCQ), yellow sulfasalazine
(SSZ), purple adalimumab biweekly, double thickness purple adalimumab weekly, grey protocol not followed as required but remained in follow up
(outside of protocol, OOP). DFR drug-free remission
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whom three died in the second year of the study
(Additional file 1).
DAS-remission and drug-free remission
Of the 610 patients, 55 (9 %) (37 with RA, 17 with UA,
p=0.01, and 1 patient who was unclassifiable because of
missing data) were in sustained DAS-remission from
4 months through to 2 years and therefore, in DFR from
8 months to 2 years. There were 50 patients (8 %) who
never achieved DAS-remission during 2 years of follow
up. Medication was reintroduced in patients who achieved
DAS-remission but lost it again after drug tapering. At the
next evaluation, 75 % of those patients were again in
DAS-remission. At the time point (t) = 2 years, 301/610
(49 %) patients were in DAS-remission and 131/610
(21 %) were in DFR. In the early remission group, 241/387
(62 %) were in DAS-remission and 111/387 (29 %) in DFR
at t = 2 years. There were 22/83 patients (27 %) in arm 1
and 24/78 (31 %) in arm 2 in DAS-remission (p=0.76),
and 6/83 patients (7 %) in arm 1 and 7/78 patients (9 %)
in arm 2 were in DFR at t = 2 years (p=0.73). Finally,
at t = 2 years, 138 of all 610 patients (23 %) were in
ACR/EULAR remission (Boolean), with 117/387 (30 %) in
the early remission group, 2/83 (2 %) in arm 1, and 14/78
(18 %) in arm 2 (arm 1 versus arm 2, p=0.001).
At t = 2 years, comparable percentages of anti-
citrullinated protein antibody (ACPA)-positive and
ACPA-negative patients were in DAS-remission (ACPA-
positive 172/333 (52 %), ACPA-negative 125/262 (48 %),
p=0.68) but more ACPA-negative patients achieved DFR
than ACPA-positive patients: 74/262 (28 %) versus 54/333
(16 %), p<0.001. Comparable percentages of UA or RA pa-
tients achieved remission after 2 years (UA 64/122 (52 %)
and RA 234/479 (49 %), p=0.25), but significantly
more UA patients, of whom 94 % were ACPA-
negative, achieved DFR (41/122 (34 %) compared to
89/479 (19 %) in RA patients, p<0.001) (Additional
file 1: Table S1).
DAS and HAQ after 2 years
Patients in DAS-remission at 2 years had a mean (SD)
HAQ of 0.29 (0.39) compared to 0.94 (0.63) in patients
who were not in remission (p<0.001), and a mean (SD)
DAS of 0.92 (0.38), compared to 2.32 (0.57) in patients
who were not in DAS-remission (p<0.001). This resulted
from significant differences in both subjective and (semi-
)objective DAS components. Symptom duration at inclu-
sion was not related to achieving or not achieving DAS-
remission at t = 2 years. Of 204 patients who at baseline
had <12 weeks symptom duration, 106 (52 %) were in
DAS-remission and 50 (25 %) were in DFR at 2 years,
compared to 192/397 (50 %) (p=0.31) and 80/397
(20 %) (p=0.19) of those who had had symptoms for
≥12 weeks.
For all patients mean (SD) DAS over time was 1.74
(0.58) and mean HAQ 0.61 (0.47). In the early remission
group this was 1.25 (0.77) and 0.38 (0.48), in arm 1 it
was 2.02 (0.70) and 0.9 (0.66), and in arm 2 it was 1.92
(0.85) and 0.83 (0.67) (Table 2 and Fig. 2). Over time,
neither DAS nor HAQ were significantly different
Table 1 Baseline characteristics of the IMPROVED study population
Total
n = 610
Early remission
n = 387
Arm 1
n = 83
Arm 2
n = 78
OOP
n = 50
DAS, mean ± SD 3.2 ± 0.9 3.0 ± 0.8 3.6 ± 0.9 3.6 ± 1.0 3.6 ± 0.9
HAQ, mean ± SD 1.2 ± 0.7 1.0 ± 0.7 1.4 ± 0.6 1.4 ± 0.6 1.3 ± 0.7
Age in years, mean ± SD 52 ± 14 52 ± 14 49 ± 14 51 ± 14 54 ± 14
Female, n (%) 414 (68) 240 (62) 64 (77) 58 (74) 42 (84)
Symptom duration (weeks), median (IQR) 18 (9–32) 17 (9–30) 22 (9–41) 21 (8–31) 18 (9–42)
RF-positive, n (%) 339 (56) 224 (58) 41 (49) 43 (55) 23 (46)
ACPA-positive, n (%) 333 (55) 225 (58) 40 (48) 37 (47) 25 (50)
RA (2010 criteria), n (%) 479 (79) 298 (77) 66 (80) 66 (85) 40 (80)
Swollen joint count, median (IQR) 5 (3–10) 5 (2–9) 6 (3–10) 8 (4–12) 7 (3–13)
Tender joint count, median (IQR) 6 (4–9) 5 (3–8) 8 (6–13) 9 (6–13) 8 (6–14)
ESR mm/h, median (IQR) 25 (11–39) 23 (8–38) 28 (13–41) 22 (11–41) 29 (16–42)
VAS global health (mm), mean ± SD 46 ± 23 43 ± 24 53 ± 20 54 ± 22 49 ± 23
Total SHS, median (IQR) 0 (0–1.0) 0 (0–0.5) 0 (0–0) 0 (0–0) 0 (0–0)
Erosive, n (%) 89 (15) 63 (16) 10 (12) 13 (17) 3 (6)
After 4 months 12 patients were lost to follow up and 598 patients were categorized as described in Table 1. Arm 1: randomized at 4 months to methotrexate,
sulphasalazine, hydroxychloroquine and low-dose prednisone. Arm 2: randomized at 4 months to methotrexate and adalimumab. OOP outside of protocol, SD
standard deviation, IQR interquartile range, n number, DAS disease activity score, HAQ health assessment questionnaire, RF rheumatoid factor, ACPA anti-citrullinated
protein antibodies, RA (2010) rheumatoid arthritis according to the 2010 classification criteria, ESR erythrocyte sedimentation rate, VAS visual analogue
scale, SHS Sharp-van de Heijde score, Erosive at least 1 erosion
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between arms 1 and 2 (mean difference (95 % CI) LMM
for DAS 0.01 (−0.2, 0.2) and for HAQ 0.1 (−0.1, 0.2))
(Fig. 2).
Radiological joint damage
Median SHS progression in all groups was 0 (range
0–22). Only 50/610 (8 %) patients had radiological
progression defined as an increase in SHS ≥0.5; in
the early remission group there were 33/387 (9 %)
patients with progression, in arm 1 there were 9/83
(11 %), in arm 2 there were 5/78 (6 %) (arm 1 versus
arm 2, p=0.31), and in the OOP group there were 3/50
(6 %). There was no significant difference in progression
score between patients who were in DAS-remission at
2 years and patients who were not. Of the 610 patients, 8
(1 %) had radiological evidence of damage progression in
≥5 points after 2 years, which represents the minimal clin-
ically important difference [30]. Seven of these eight
patients were in early remission after 4 months and ta-
pered prednisone to zero, after which five patients re-
lapsed, needing to restart prednisone. One patient did not
achieve early remission and was randomized to arm 2.
After 2 years, erosions were seen on radiographs of the
hands or feet in 39/387 (10 %) of patients in the early re-
mission group, in 2/83 (2 %) in arm 1, in 8/78 (10 %) in
arm 2 (arm 1 versus arm 2, p=0.04), and in 1/50 (2 %) of
patients in the OOP group.
Therapy
The percentages of patients on various medications ac-
cording to the prescribed treatment steps per 4 months
in the early remission group, in arm 1, and in arm 2 are
depicted in Fig. 3. In the early remission group treat-
ment with prednisone decreased from 100 % of patients
at treatment start to less than 10 % at t = 2 years (Fig. 3a).
Having all also started with MTX treatment, 45 % still
Table 2 Outcomes in the IMPROVED-study population after 2 years
Total
n = 610
Early remission
n = 387
Arm 1
n = 83
Arm 2
n = 78
P value
arm 1 vs 2
OOP
n = 50
DAS, mean ± SD 1.5 ± 0.8 1.3 ± 0.8 2.0 ± 0.7 1.9 ± 0.9 0.45 1.9 ± 0.7
HAQ, mean ± SD 0.5 ± 0.6 0.4 ± 0.5 0.9 ± 0.7 0.8 ± 0.7 0.55 0.8 ± 0.7
Swollen joint count, median (IQR) 0 (0–1) 0 (0–1) 1 (0–2) 0 (0–2) 0.25 0 (0–2)
Tender joint count, median (IQR) 1 (0–3) 0 (0–2) 3 (2–5) 3 (1–6) 0.84 2 (1–4)
ESR mm/h, median (IQR) 9 (5–17) 8 (4–16) 11 (6–20) 9 (6–17) 0.19 14 (7–25)
VAS global health (mm), mean ± SD 22 ± 22 18 ± 21 30 ± 21 28 ± 24 0.61 32 ± 22
Total SHS, median (IQR) 0 (0–0.5) 0 (0–0.5) 0 (0–1.1) 0 (0–0) 0.12 0 (0–0.3)
Erosive, n (%) 50 (8) 39 (10) 2 (2) 8 (10) 0.04 1 (2)
SHS progression, n (%) 50 (8) 33 (9) 9 (11) 5 (6) 0.31 3 (6)
DAS-remission, n (%) 301 (49) 241 (62) 22 (27) 24 (31) 0.76 14 (28)
Drug-free remission, n (%) 131 (22) 111 (29) 6 (7) 7 (9) 0.73 7 (14)
ACR/EULAR remission, n (%) 138 (23) 117 (30) 2 (2) 14 (18) 0.001 5 (10)
After 4 months 12 patients were lost to follow up and 598 patients were categorized. Arm 1: randomized after 4 months to methotrexate, sulphasalazine,
hydroxychloroquine and low-dose prednisone. Arm 2: randomized after 4 months to methotrexate and adalimumab. OOP outside of protocol, SD standard
deviation, IQR interquartile range, n number, DAS disease activity score, HAQ health assessment questionnaire, ESR erythrocyte sedimentation rate, VAS
visual analogue scale, SHS Sharp-van de Heijde score, Erosive at least 1 erosion, Progression increase in SHS ≥0.5 points, DAS-remission DAS <1.6 [24],
ACR/EULAR remission provisional Boolean-based remission definition published by the American College of Rheumatology and the European League
Against Rheumatism based on a 44-joint count [26]
Fig. 2 Mean disease activity score (DAS) and health assessment questionnaire (HAQ) according to treatment group during 2 years of follow up.
OOP outside of protocol
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used MTX at t = 2 years. In the early remission group
15 % of patients, after having lost DAS-remission, did
not regain DAS-remission after restart of prednisone,
and were randomized to arm 1 or 2.
In arm 1, over 2 years of treatment 52/83 (63 %)
patients failed to achieve DAS-remission on the com-
bination of MTX with sulfasalazine, hydroxychloro-
quine and prednisone and started on adalimumab
(with MTX), and up to 39 % of these increased adali-
mumab to once weekly by protocol. Over time, most
patients discontinued adalimumab, but due to late
switchers and also restarters because of DAS ≥1.6,
after 2 years 40 % of patients in arm 1 were using
adalimumab. In arm 2, 40 % of patients randomized
to treatment with adalimumab initially increased the
dose to 40 mg/week at month 8. The percentage of
patients on adalimumab decreased during 2 years of
treatment to 36 % (Fig. 3c), despite this. The main
difference between arms 1 and 2 thus constitutes the
higher initial use of adalimumab in arm 2, while ada-
limumab use levelled out to around 40 % of patients
at year 2 in both arms. In addition, more patients in
arm 2 progressed to other medications. No details are
available for the OOP group, in whom treatment
remained steered at remission, but with medication
not as prescribed in the protocol.
Toxicity
Details on toxicity in year 1 were reported previously
[22], showing no significant differences between the
treatment arms. During the second year of the study,
337/610 (55 %) patients reported 704 adverse events
(AE), 53 % of the patients in the early remission
group, 64 % in arm 1, 67 % in arm 2 (arm 1 versus
arm 2, p=0.71), and 54 % in the OOP group. The most
common AE were gastrointestinal complaints, upper
airway infections, and skin rashes (Table 3). Twenty-five
serious adverse events (SAE) were reported in the early
remission group, five in arm 1, eight in arm 2, and three
in the OOP group (Additional file 2: Table S2).
Discussion
Two years after initial therapy with MTX and a ta-
pered high dose of prednisone, followed by DAS-
remission-steered treatment including drug tapering
and discontinuation, 49 % of the patients with early
Fig. 3 Treatment over time in the early remission group (a), Arm 1 (b) and Arm 2 (c), in percentage of total per treatment group; percentages
in disease activity score (DAS)-remission and percentages in drug-free remission (DFR) (d). a Early remission group; b Arm 1; c. Arm 2. Lines are
approximations of the proportions of patients discontinuing medication (according to tapering strategies or due to side effects), or starting
medications according to DAS-remission-steered escalation strategies, across various treatment steps per arm, over time. The category Other
includes medications that were prescribed per protocol in the ‘treatment according to rheumatologist’ step after failure on methotrexate plus
adalimumab, and medications prescribed outside of the protocol but still maintaining a DAS-remission-targeted strategy. Shaded areas denote
patient proportions in DAS-remission over time. d. Proportions of patients in DAS-remission and DFR per strategy over time. MTX methotrex-
ate, pred prednisone, SSZ sulphasalazine, HCQ hydroxychloroquine, ADA adalimumab, mono monotherapy, DFR drug-free (DAS) remission, LTFO
lost to follow up, ER early remission
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RA or UA were in DAS-remission, and 21 % were in DFR.
Patients who achieved early DAS-remission after 4 months
more often achieved DAS-remission over time (62 % at
2 years) and DFR (29 % at 2 years) than patients who did
not (29 % DAS-remission and 9 % DFR at 2 years). There
were no differences between the two treatment strategies.
Mean DAS over time was significantly lower in the early
remission group than in the other groups, but due to
DAS-remission-steered treatment, mean (SD) DAS over
time was low (1.74 (0.58)) across all patients. Radiological
evidence of damage progression ≥0.5 SHS was seen in
only 8 % of the patients and functional ability improved
up to the normal range in those who achieved remission
and was slightly lower in the other groups.
The study shows the effectiveness of early DAS-
remission-steered therapy, resulting in low disease
activity, improved functional ability and prevention of
damage progression. In particular, the radiologic results
Table 3 Number of adverse events reported between 1 year and 2 years
Early remission
n = 387
Arm 1
n = 83
Arm 2
n = 78
OOP
n = 50
Patients with AE*, n (%) 205/387 (53 %) 53/83 (64 %) 52/78 (67 %) 27/50 (54 %)
Total number of AE 408 129 109 58
Cardiovascular 25 5 8 4
Pulmonary 17 5 2 2
Gastrointestinal 67 16 14 12
GI complaints 8 2 2 –
Nausea/emesis 23 2 4 4
Increased liver enzymes 15 7 3 4
Other 21 5 5 4
Neuro-psychiatric 37 5 7 3
Headache 14 – 4 1
Dizziness 7 1 – 1
Mood disorders 4 – – 1
Other 12 4 3 –
Urogenital 7 3 2 3
Skin/mucous membranes 45 18 15 3
Rash 19 8 5 –
Hair loss/thinning 4 1 1 1
Sicca complaints 3 – – 1
Eczema 3 1 – –
Other 16 8 9 1
Infections 106 38 41 18
Upper airway tract 29 11 16 10
Gastrointestinal 4 1 – 2
Skin/mucosa 14 2 4 2
Pneumonia/bronchitis 9 1 1 1
Urinary tract 15 7 5 1
Influenza/unspecified fever 25 10 6 1
Other 10 6 9 1
Trauma/injury 13 5 2 3
Infusion reaction 3 1 – –
Malaise 9 5 1 1
Surgical procedures without hospitalization 13 5 4 1
Other 65 23 12 8
*One or more adverse events possible per patient. OOP outside of protocol, AE adverse events, GI gastrointestinal
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are better than in previous studies such as the
remission-steered NEO-RACo study in which 20–47 %
of the patients had progression after 2 years, and bet-
ter than in the DAS ≤2.4-steered BeSt study, in which
7–33 % of the patients across the four treatment
arms had progression after 1 year [14, 17]. This is all
the more remarkable as unlike in these studies, we
introduced rapid tapering and discontinuation of
medication in this study to aim for early DFR. The
virtual absence of radiographic evidence of joint dam-
age progression, which is mainly a pathophysiological
important outcome as minimal damage has little clin-
ical relevance [31], may be related to several trial as-
pects. We included patients with earlier disease and
milder disease activity and less damage at baseline,
and with fewer ACPA-positive patients than in the
FIN-RACo, NEO-RACo and BeSt studies. As in the
BeSt and COBRA study, we started treatment with a
combination of high-dose MTX and a tapered high
dose of prednisone, leaving out sulphasalazine, as in
the COBRA-light study [20], which has subsequently
shown that a lower dose of prednisone is not less
effective than a high dose of prednisone. In addition,
we designed the study to be able to introduce a TNF-
inhibitor early in the disease course if DAS-remission
was not achieved, also for patients with arthritis who
were suspected to have early RA, who did not fulfil
the classification criteria.
The clinical data are maybe not as spectacular. We
had hypothesized that early remission-steered treatment
including the initial high dose MTX and prednisone and
option to expand or switch to multiple conventional
synthetic (cs)DMARD or adalimumab, would result in
induction of permanent remission in a large number of
patients with early arthritis in this study population. Yet,
the overall DAS-remission rates of 49 % in the IM-
PROVED study are lower than in the NEO-RACo study
(60.5 %) [17] and only slightly higher than what we ob-
served in the BeSt study (42 %) [14, 16].
The initial findings were promising. More than 60 %
of patients achieved DAS-remission after 4 months of
treatment, and of those, more than 30 % were in drug-
free remission by the end of year 1, and 29 % were in
drug-free remission after 2 years. Those not in early re-
mission were randomized to two effective treatment op-
tions, with the hypothesis that earlier introduction of
anti-TNF might result in more remission and better
functional ability. After 1 year we found that patients in
arm 2, who were randomized to treatment with adalimu-
mab, achieved more DAS-remission than patients who
were randomized to first try therapy with triple-
csDMARDs plus low-dose-prednisone [22]. The weekly
dose of adalimumab (in combination with MTX) was ex-
ploratory and is not evidence based. In current daily
practice this is not approved, based on the costs of this
medication and the dose-dependent risk of infection and
malignancy [25]. Fortunately our patients who were
treated with this combination of therapy did not have
significantly more serious infections or malignancies.
After 2 years of DAS-remission-steered therapy, this
difference was no longer evident. Similar results were
found in the SWEFOT trial [32]. and the RACAT trial
[33]. Initial improvement may depend on choice of ini-
tial therapy, but late outcomes depend on subsequent
targeted treatment. Although delaying adalimumab in
arm 1 may have delayed achieving DAS-remission in a
proportion of patients, and there were only 2 patients in
ACR/EULAR Boolean remission (compared to 14 in arm
2), this has had no relevant impact on radiologic out-
comes, nor on the possibility to taper and stop adalimu-
mab (Fig. 3). This is contrary to what we previously
found in the BeSt study [16, 34, 35], in which delayed
treatment with a TNF-inhibitor was associated with
more maintained treatment with that TNF-inhibitor
over time.
We were able to taper and stop medication in many
patients, effectively avoiding prolonged use of prednis-
one and (although less so) adalimumab (Fig. 3) and
achieving one in five patients being in drug-free (DAS)
remission at year 2. However, more patients achieved re-
mission and tapered medication; the majority then had a
DAS >1.6 and medication had to be escalated again. It
can be argued that we should not have tapered, or
tapered and stopped the medication too fast. A longer
induction treatment might have suppressed the disease
more permanently. Drug-free remission in the BeSt
study was introduced after up to 2 years of low disease-
activity and 6 months of DAS-remission. Still 50 % of
patients who achieved drug-free remission had to restart
medication because of DAS ≥1.6 [36]. Continuous
treatment during DAS-remission would have little im-
pact on the radiological outcomes and could induce
more side effects. In daily practice, one could con-
sider tapering more slowly or having a maintenance
dose, or substituting methotrexate with hydroxychlor-
oquine before stopping completely, but we cannot
support that with evidence.
We found that the overall remission rates were rela-
tively low because patients who did not achieve early re-
mission were also less likely to achieve remission later
on. It might be that for the window of opportunity was
already missed, even though the outcomes between
patients with <12 weeks symptom duration and those
with ≥12 weeks symptom duration were comparable. Re-
mission rates and other outcomes (except for DFR) were
also comparable between patients with RA and UA.
Patients who did not achieve early remission may repre-
sent a selected group with more advanced and less
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responsive disease, who already had a higher HAQ score
at baseline. Some of these patients may have had non-
inflammatory symptoms or non-RA-related erythrocyte
sedimentation rate (ESR) that may have influenced the
DAS but would not respond to antirheumatic treatment.
For these patients a DAS <1.6 may be unrealistic and
remission-steered treatment adjustments may constitute
overtreatment. By including and treating patients with
UA we risked treating patients with a self-limiting non-
RA type of arthritis, who would be among the patients
who achieved DFR. At 2 years, 29 % of patients in the
early remission group and 7–9 % in arms 1 and 2 were
in DFR, which is a percentage not too different form
the 25 % of UA patients who achieved spontaneous
remission in the PROMPT trial [10]. We found that
UA patients more often achieved DFR than RA pa-
tients, and anti-citrullinated protein antibody (ACPA)-
negative patients more often than ACPA-positive pa-
tients. Interestingly, ACPA positivity was associated
with achieving early DAS-remission at 4 months [13],
and after 1 year of treatment, DAS-remission while
on medication was achieved in RA and UA patients,
and in ACPA-positive and ACPA-negative patients in
comparable percentages. It appears that RA patients
and ACPA-positive patients who achieved DAS-
remission will more often flare when medication is ta-
pered and stopped. This may affect future trial design
and daily practice.
Conclusion
After 2 years of remission-steered treatment in pa-
tients with early RA and UA, DAS-remission and
DFR percentages were relatively low. Patients who
achieved early remission more often achieved (drug-
free) remission after 2 years than patients who needed
additional treatment steps in the randomization arms,
and more UA than RA patients achieved DFR. Dam-
age progression as seen on radiographs was well sup-
pressed in all patients. As suppression of radiologic
damage progression is not enough, additional therap-
ies, medicinal or other, should be investigated to
improve clinical outcomes without risk of significant
side effects, and further investigations should focus
on identifying predictive factors or early markers of
effective suppression of disease activity on the initial
therapy, to choose the next treatment step and avoid
delays in clinical response.
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